16 results about "Dna antibody" patented technology

The application provides a preparation of a sema7A monoclonal antibody 8A12 and a treatment effect of the sema7A monoclonal antibody 8A12 on lupus nephritis, wherein the CDR-H1 of the heavy chain variable region of the monoclonal antibody 8A12 is an amino acid sequence shown in SEQ ID No. 1, the CDR-H2 of the heavy chain variable region is an amino acid sequence shown in SEQ ID No. 2, and the CDR-H3 of the heavy chain variable region is an amino acid sequence shown in SEQ ID No. 3; the CDR-L1 of the light chain variable region of the monoclonal antibody 8A12 is an amino acid sequence shown in SEQ ID No. 4, the CDR-L2 of the light chain variable region is an amino acid sequence shown in SEQ ID No. 5, and the CDR-L3 of the light chain variable region is an amino acid sequence shown in SEQ ID No. 6. The monoclonal antibody 8A12 can effectively inhibit the expression up-regulation of IL-1beta, TNF-alpha and IL-6 caused by Sema7A recombinant protein, can effectively inhibit the macrophage inflammatory response induced by Sema7A, and can continuously and effectively reduce serum anti-double-stranded DNA antibodies and kidney damage of lupus mice. The monoclonal antibody 8A12 can be used for preparing a pharmaceutical composition for preventing and / or treating systemic lupus erythematosus and / or lupus nephritis thereof.

The invention provides an anti-double-stranded DNA antibody indirect immunofluorescence method picture interpretation method and device and a medium, and the method comprises the following steps: obtaining a to-be-collected slide which is obtained by treating a to-be-detected serum sample through an anti-double-stranded DNA indirect immunofluorescence method; performing image acquisition on the to-be-acquired slide to obtain an acquired image set corresponding to the to-be-acquired slide; performing image processing on the acquired image set to obtain a first target image set; performing image processing on the first target image set to obtain a cell region corresponding to each first target image in the first target image set; and performing identification processing on the cell region corresponding to each first target image to obtain a sample report of the to-be-collected slide. According to the method, a series of steps of image acquisition, processing, cell region identification and the like are adopted for processing, so that the traditional manual operation is replaced, the automation of the interpretation process is realized, and the interpretation accuracy and efficiency are improved.

The invention provides an anti-double-stranded DNA antibody detection kit and application thereof. The kit comprises a detection card and a dilution solution, wherein the dilution solution is used for diluting a sample to be detected; the detection card comprises a test strip, wherein the test strip comprises a sample pad, a combination pad, an NC membrane and a water absorption pad which are arranged in sequence; wherein the nitrocellulose membrane is sequentially provided with a detection line and a quality control line, the quality control line is arranged close to the water absorption pad relative to the detection line, the detection line is coated with a double-stranded DNA antigen, and the quality control line is coated with a third antibody; a first fluorescently-labeled antibody and a second fluorescently-labeled antibody are loaded on the combination pad, the first antibody can be specifically combined with an anti-double-stranded DNA antibody, and the second antibody can be specifically combined with a third antibody. The kit provided by the invention is wide in detection range, low in detection limit and high in sensitivity, and has good repeatability and specificity.

The application relates to an ANA and dsDNA fluorescence image processing method, device and computer equipment. The method comprises the following steps: acquiring a fluorescence microscope shooting image; in response to a detection item selection operation on the fluorescence microscope shooting image, determining a detection item identifier associated with the fluorescence microscope shooting image; according to the detection item identifier associated with the fluorescence microscope shooting image, distributing the fluorescence microscope shooting image to a corresponding image detection pipeline, so that the image detection pipeline detects and processes the fluorescence microscope shooting image according to an image detection algorithm process matched with the detection item identifier, and obtains a structured detection result corresponding to the fluorescence microscope shooting image; and displaying the structured detection result corresponding to the fluorescence microscope shooting image. The method can improve the laboratory detection efficiency of an anti-nuclear antibody and an anti-double-stranded DNA antibody fluorescence image.

Use of naphthoquine phosphate in preparation of a medicament for treating autoimmune diseases. It is proved in a mouse rheumatoid arthritis model that the intragastric administration of naphthoquine phosphate can remarkably ameliorate symptoms such as joint redness, swelling, and deformities and reduce the levels of antigen-specific antibodies. It is proved in a mouse systemic lupus erythematosus model that the intragastric administration of naphthoquine phosphate can remarkably reduce the levels of anti-double-stranded DNA antibodies and anti-nuclear antibodies. Pharmacodynamic and pharmacological studies prove that naphthoquine phosphate has ideal immunosuppressive activity and can be used to prepare the medicament for treating autoimmune diseases. Further provided is a pharmaceutical use of naphthoquine phosphate in the treatment and auxiliary treatment of rheumatoid arthritis or systemic lupus erythematosus. The medicament is a pharmaceutical composition consisting of a therapeutically effective amount of naphthoquine phosphate serving as an active ingredient and pharmaceutical excipients.

The present disclosure is directed to methods for treating a neuropsychiatric disorder associated with expression of autoantibodies to ionotropic glutamate receptor, NMD A 2A (GiuN2A), expression of anti-double-stranded (ds) DNA antibodies that cross react with one or more subunits of the NMD A receptor, or a mutation in the ionotropic glutamate receptor NMD A type subunit 2A (GRIN2A) gene. The methods involve administering a memantine, or a pharmaceutically acceptable salt thereof, to a subject suffering from a neuropsychiatric disorder associated with expression of GluN2A or a mutation in the GRIN2A gene.

A method for identifying MRL / lpr lupus renal organoids, specifically collecting organoid culture medium to be tested, detecting the levels of ANA and anti-ds-DNA antibodies in the culture medium, and performing histomorphological identification of the organoids. The present invention identifies the histomorphology of MRL / lpr lupus mouse renal organoids by detecting the levels of ANA and anti-ds-DNA antibodies, as well as HE staining and immunofluorescence, thereby detecting whether the MRL / lpr lupus renal organoids have been successfully constructed.

Disclosed herein are compositions comprising a recombinant nucleic acid sequence for generating one or more synthetic antibodies, including a DNA-encoded monoclonal antibody targeting influenza A virus hemagglutinin (HA) protein and a DNA- encoded monoclonal antibody targeting influenza A virus neuraminidase (NA) protein, compositions comprising a recombinant nucleic acid sequence for generating one or more immunogen, including influence A nucleoprotein (NP) and influenza A virus hemagglutinin (HA) protein. The disclosure also provides a method of preventing and / or treating influenza in a subject using said composition.

Compositions for improved gene editing and methods of use thereof are disclosed. In a preferred method, gene editing involves use of a cell-penetrating anti-DNA antibody, such as 3E10, as a potentiating agent to enhance gene editing by nucleases and triplex forming oligonucleotides. Genomic modification occurs at a higher frequency when cells are contacted with the potentiating agent and nuclease or triplex forming oligonucleotide, as compared to the absence of the potentiating agent. The methods are suitable for both ex vivo and in vivo approaches to gene editing and are useful for treating a subject with a genetic disease or disorder. Nanoparticle compositions for intracellular delivery of the gene editing compositions are provided and are particularly advantageous for use with in vivo applications.

The invention discloses a kit for detecting an anti-DNA antibody, and belongs to the technical field of kits.The kit for detecting the anti-DNA antibody comprises a shell, a plurality of reagent tubes are arranged in the shell, the upper end of the shell is fixedly connected with a first fixing plate, and the lower surface in the shell is fixedly connected with a plurality of lifting mechanisms; a fool-proof plate is fixedly connected to the side, close to the lifting mechanism, of the shell, a locking mechanism is fixedly connected into the shell, a plurality of round holes are formed in a first fixing plate, the reagent tube comprises a tube body which penetrates through the round holes and is slidably connected with the round holes, a plug is fixedly connected to the lower end of the tube body, and a plurality of grooves are formed in the periphery of the plug. By using the locking mechanism and the lifting mechanism, reagent tubes can be conveniently taken and placed, meanwhile, the reagent tubes are prevented from being knocked over, the stability of the reagent tubes is improved, and meanwhile, objects in the reagent tubes are prevented from being spilled out due to too high speed when the reagent tubes are lifted.

The application provides a preparation of a strain of anti-sema7A functional monoclonal antibody 10A6 and an anti-inflammatory effect of the monoclonal antibody 10A6 in SLE, wherein the CDR-H1 of the heavy chain variable region of the monoclonal antibody 10A6 is an amino acid sequence shown in SEQ ID No. 1, the CDR-H2 of the heavy chain variable region is an amino acid sequence shown in SEQ ID No. 2, and the CDR-H3 of the heavy chain variable region is an amino acid sequence shown in SEQ ID No. 3; the CDR-L1 of the light chain variable region of the monoclonal antibody 10A6 is an amino acid sequence shown in SEQ ID No. 4, the CDR-L2 of the light chain variable region is an amino acid sequence shown in SEQ ID No. 5, and the CDR-L3 of the light chain variable region is an amino acid sequence shown in SEQ ID No. 6. The monoclonal antibody 10A6 can effectively inhibit the expression up-regulation of IL-1beta, TNF-alpha and IL-6 caused by Sema7A recombinant protein; the anti-sema7A monoclonal antibody 10A6 can effectively inhibit the macrophage inflammatory response induced by Sema7A, continuously and effectively reduce the serum anti-double-stranded DNA antibody of a lupus mouse. The monoclonal antibody 10A6 can be used for preparing a pharmaceutical composition for preventing and / or treating systemic lupus erythematosus.

Disclosed herein are compositions for generating a synthetic antibody or synthetic multivalent antibody in a subject. Also disclosed are methods for generating a synthetic antibody or synthetic multivalent antibody in a subject by administering a composition including one or more recombinant nucleic acid sequence that encodes a synthetic antibody or synthetic multivalent antibody to the subject. The disclosure also provides a compositions and methods of preventing and / or treating a Neisseria gonorrhoeae infection in a subject using said synthetic antibody or synthetic multivalent antibody.

Disclosed herein are mono and bispecific DNA antibodies (DMAbs) targeting Pseudomonas aeruginosa. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the DMAbs to the subject. The disclosure also provides a method of preventing and / or treating Pseudomonas aeruginosa infection in a subject using said composition and method of generation.

Methods of detecting biomarkers in a blood sample obtained from a human subject include detecting an erythrocyte-bound C4d (EC4d) marker, a B-lymphocyte-bound C4d (BC4d) marker, and an anti-nuclear antibody (ANA) in the blood sample; and detecting a level of double-stranded DNA antibody in the blood sample, wherein the human subject is negative for systemic lupus erythematosus based on the level of double-stranded DNA antibody. The methods optionally further include determining a systemic lupus erythematosus risk score by: (a) adjusting the level of EC4d marker by a weighting coefficient to produce a weighted score for EC4d marker; (b) adjusting the level of BC4d marker by a weighting coefficient to produce a weighted score for BC4d marker; (c) adjusting the level of ANA by a weighting coefficient to produce a weighted score for ANA; and (d) combining the weighted score for EC4d marker, the weighted score for BC4d marker, and the weighted score for ANA to generate the systemic lupus erythematosus risk score; wherein the systemic lupus erythematosus risk score does not include a score for double-stranded DNA antibody.

Disclosed herein is an antibody to pneumococcal histidine triad protein D (PhtD) as well as nucleic acid molecules encoding the anti-PhtD antibody and compositions comprising the antibody or nucleic acid molecules encoding the antibody. The disclosure also provides a method of preventing and / or treating a bacterial infection in a subject using the antibody or nucleic acid molecules.

Disclosed herein are compositions for generating a synthetic antibody or synthetic multivalent antibody in a subject. Also disclosed are methods for generating a synthetic antibody or synthetic multivalent antibody in a subject by administering a composition including a recombinant nucleic acid sequence that encodes an antibody, a synthetic antibody, or a synthetic multivalent antibody to a subject. The disclosure also provides compositions and methods of preventing and / or treating a bacterial infection in a subject using said antibody, synthetic antibody, or synthetic multivalent antibody.